Somnolence syndrome after focal radiation therapy to the pineal region: case report and review of the literature
- 171 Downloads
Somnolence syndrome classically occurs in children after cranial irradiation for acute lymphocytic leukemia. Symptoms include somnolence, fever, nausea and vomiting, and headache. The authors report a 29 year-old female who developed symptoms compatible with the somnolence syndrome after completing radiation therapy for a benign meningioma near the pineal region. Five weeks after completing conformal radiation therapy (54 Gy), she developed profound fatigue, headaches, and 102° fevers. Physical examination and routine laboratory work were unrevealing. Imaging was not performed. Prednisone was prescribed and within 1 week her symptoms had largely resolved. This is the first report of the somnolence syndrome after focal radiation therapy. The possible etiology of the somnolence syndrome is discussed.
Keywordsearly delayed encephalopathy pineal region radiation therapy radiation-induced brain injury somnolence syndrome
acute lymphocytic leukemia
reticular activating system
Unable to display preview. Download preview PDF.
- 2.Druckmann A: Schlafsuct als forge der roentegenbestrahlung beitragzur strahlenempfindlichkeit des gehuna Strahlentherapie 33: 382–384, 1929Google Scholar
- 9.Leibel S, Sheline G: Tolerance of the Brain and Spinal Cord to Conventional Irradiaiton. In: Gutin P, Leibel S, Sheline G (eds) Radiation Injury to the Nervous System Raven Press, New York, pp 239–241Google Scholar
- 14.Buckner JC, Schomberg PJ, McGinnis WL, Cascino TL, Scheithauer BW, O’Fallon JR, Morton RF, Kuross SA, Mailliard JA, Hatfield AK, Cole JT, Steen PD, Bernath AM: A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma Cancer 92: 420–433, 2001CrossRefPubMedGoogle Scholar
- 15.Merchant RE, McVicar DW, Merchant LH, Young HF: Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial J Neurooncol 12 75–83, 1992CrossRefPubMedGoogle Scholar